SCHEMBL6580387

SCHEMBL6580387

CCCCC(=O)c1c(-c2ccc3c(Br)c(O)ccc3c2)oc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 0.51
LMNA P02545 2/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TTR P02766 2/20 0.41
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
ESR1 P03372 3/20 0.40
ESR2 Q92731 2/20 0.40
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
BCHE P06276 1/20 0.38
CYP2C19 P33261 3/20 0.38
MEN1 O00255 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPT P10636 2/20 0.38
CYP2C9 P11712 2/20 0.38
MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6579758 0.87 ALOX5 (0.42) PTPN1LMNAHTTSMN1; SMN2HSD17B1
SCHEMBL6581329 0.86 PTPN1 (0.43) PTPN1LMNANPC1TTRHSD17B1
SCHEMBL6581446 0.84 LMNA (0.53) PTPN1LMNAHTTNPC1RAB9A
SCHEMBL6581487 0.84 PTPN1 (0.58) PTPN1LMNAHTTKDM4EALDH1A1
SCHEMBL6581594 0.83 PTPN1 (0.47) PTPN1LMNAHTTNPC1RAB9A
SCHEMBL6579721 0.82 PTPN1 (0.48) PTPN1LMNAHTTNPC1RAB9A
SCHEMBL6584870 0.81 L3MBTL1 (0.48) PTPN1HSD17B1HSD17B2ESR1ESR2
SCHEMBL6579618 0.81 PTPN1 (0.68) PTPN1PPARG
SCHEMBL6579567 0.81 PTPN1 (0.61) PTPN1HSD17B1HSD17B2ESR1ESR2
SCHEMBL6582215 0.81 CNR2 (0.56) LMNAHTTNPC1SMN1; SMN2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP disclosed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US disclosed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US disclosed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) F2R, SERPINE1, SERPINC1 PTPN1 1287/4885LMNA 903/4885HTT 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.